CYSLTR2 and neoplasm: Recently, mutations of several genes such as GNAQ, GNA11, BAP1, SF3B1, EIF1AX, PLCB4, and CYSLTR2 have been identified in UM.43 In particular, loss-of-function mutations of BAP1 gene are found to be associated with a poor outcome in 84% of metastatic UM patients, hinting a tumor suppressor role of BAP1 in metastasis.